American Oriental Bioengineering Inc
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respir… Read more
American Oriental Bioengineering Inc (AOBI) - Net Assets
Latest net assets as of September 2013: $283.68 Million USD
Based on the latest financial reports, American Oriental Bioengineering Inc (AOBI) has net assets worth $283.68 Million USD as of September 2013.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($427.62 Million) and total liabilities ($143.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $283.68 Million |
| % of Total Assets | 66.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | -5.28% |
| 10-Year Change | 1669.74% |
| Growth Volatility | 572.47 |
American Oriental Bioengineering Inc - Net Assets Trend (2000–2012)
This chart illustrates how American Oriental Bioengineering Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for American Oriental Bioengineering Inc (2000–2012)
The table below shows the annual net assets of American Oriental Bioengineering Inc from 2000 to 2012.
| Year | Net Assets | Change |
|---|---|---|
| 2012-12-31 | $327.59 Million | -14.06% |
| 2011-12-31 | $381.16 Million | -11.54% |
| 2010-12-31 | $430.90 Million | +9.07% |
| 2009-12-31 | $395.06 Million | +14.22% |
| 2008-12-31 | $345.86 Million | +10.47% |
| 2007-12-31 | $313.08 Million | +100.47% |
| 2006-12-31 | $156.18 Million | +72.37% |
| 2005-12-31 | $90.60 Million | +173.40% |
| 2004-12-31 | $33.14 Million | +79.04% |
| 2003-12-31 | $18.51 Million | +119.45% |
| 2002-12-31 | $8.43 Million | +2036.64% |
| 2001-12-31 | $394.77K | +176.62% |
| 2000-12-31 | $-515.22K | -- |
Equity Component Analysis
This analysis shows how different components contribute to American Oriental Bioengineering Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7993413800.0% over the analyzed period, indicating profitable operations and earnings retention.
- The company has 0.2% of equity in treasury stock, representing shares repurchased from the open market.
Current Equity Component Breakdown (December 2012)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $78.10 Million | 23.84% |
| Common Stock | $523.90K | 0.16% |
| Treasury Stock | $800.00K | 0.24% |
| Other Comprehensive Income | $71.79 Million | 21.91% |
| Other Components | $177.98 Million | 54.33% |
| Total Equity | $327.59 Million | 100.00% |
American Oriental Bioengineering Inc Competitors by Market Cap
The table below lists competitors of American Oriental Bioengineering Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DIGITAL 9 INFRASTRUCTURE
F:6DJ
|
$4.65 |
|
SUNRISE RESOURCES (S4D.SG)
STU:S4D
|
$4.68 |
|
Millennium Prime Inc
PINK:MLMN
|
$4.69 |
|
Xalles Holdings Inc
PINK:XALL
|
$4.70 |
|
Golden Triangle Ventures Inc
PINK:GTVH
|
$4.65 |
|
Gold And Gemstone
PINK:GGSM
|
$4.63 |
|
BARON OIL
BE:GHA
|
$4.62 |
|
U-Swirl Inc
PINK:SWRL
|
$4.62 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in American Oriental Bioengineering Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2011 to 2012, total equity changed from 381,698,314 to 327,586,706, a change of -54,111,608 (-14.2%).
- Net loss of 59,713,000 reduced equity.
- Share repurchases of 1,270,603 reduced equity.
- Other comprehensive income increased equity by 4,066,797.
Equity Change Factors (2011 to 2012)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.71 Million | -18.23% |
| Share Repurchases | $1.27 Million | -0.39% |
| Other Comprehensive Income | $4.07 Million | +1.24% |
| Other Changes | $2.81 Million | +0.86% |
| Total Change | $- | -14.18% |
Book Value vs Market Value Analysis
This analysis compares American Oriental Bioengineering Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-1610.06 | $0.00 | x |
| 2001-12-31 | $39.01 | $0.00 | x |
| 2002-12-31 | $794.31 | $0.00 | x |
| 2003-12-31 | $592.66 | $0.00 | x |
| 2004-12-31 | $978.03 | $0.00 | x |
| 2005-12-31 | $2070.87 | $0.00 | x |
| 2006-12-31 | $2487.37 | $0.00 | x |
| 2007-12-31 | $4395.94 | $0.00 | x |
| 2008-12-31 | $4205.29 | $0.00 | x |
| 2009-12-31 | $4427.47 | $0.00 | x |
| 2010-12-31 | $5695.10 | $0.00 | x |
| 2011-12-31 | $5110.98 | $0.00 | x |
| 2012-12-31 | $4285.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently American Oriental Bioengineering Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.15%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.36x
- Recent ROE (-18.23%) is below the historical average (33.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -2367.68% | 0.36x | 0.00x | $-486.06K |
| 2001 | 333.36% | 16.79% | 19.82x | 1.00x | $1.28 Million |
| 2002 | 13.36% | 11.05% | 0.94x | 1.29x | $283.52K |
| 2003 | 24.86% | 22.06% | 0.96x | 1.17x | $2.75 Million |
| 2004 | 23.45% | 24.31% | 0.75x | 1.29x | $4.46 Million |
| 2005 | 14.82% | 24.53% | 0.55x | 1.10x | $4.37 Million |
| 2006 | 18.70% | 26.50% | 0.59x | 1.19x | $13.58 Million |
| 2007 | 13.83% | 26.98% | 0.45x | 1.13x | $11.98 Million |
| 2008 | 13.63% | 17.78% | 0.50x | 1.52x | $12.54 Million |
| 2009 | 10.50% | 13.99% | 0.51x | 1.46x | $1.97 Million |
| 2010 | 3.27% | 4.60% | 0.50x | 1.42x | $-28.95 Million |
| 2011 | -17.94% | -32.20% | 0.38x | 1.48x | $-106.66 Million |
| 2012 | -18.23% | -41.15% | 0.33x | 1.36x | $-92.47 Million |
Industry Comparison
This section compares American Oriental Bioengineering Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| American Oriental Bioengineering Inc (AOBI) | $283.68 Million | 0.00% | 0.51x | $4.65 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |